12:00 AM
 | 
Jul 16, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Halaven eribulin mesylate: Preliminary Phase III data

Preliminary data from the open-label, international Phase III Study 301 trial in 1,102 patients showed that Halaven missed the co-primary endpoints of OS and PFS vs. Xeloda capecitabine. Details were not disclosed. The trial enrolled women with locally advanced or metastatic breast cancer who were previously treated with anthracyclines and taxanes either in the adjuvant setting or for locally advanced or...

Read the full 292 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >